Pancreatic Cancer Research

ResearcherSeoul National UniversityNo recent work listed

Kyung-Hun Lee

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2390-3240; OpenAlex author ID A5101886232. Sources: OpenAlex.

Their work

Papers
13 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
45
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: 1 paper · 2016: 5 papers · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: 2 papers · 2021: 1 paper · 2022: none · 2023: 1 paper

Papers 13

  1. Combination of chemotherapy and focused ultrasound for the treatment of unresectable pancreatic cancer: a proof-of-concept study. Co-author DOI 10.1007/s00330-022-09271-8↗
  2. Phase II Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiotherapy with Gemcitabine in Patients with Resected Pancre… Co-author DOI 10.4143/crt.2020.928↗
  3. Survival benefit of adjuvant chemoradiotherapy for positive or close resection margin after curative resection of pancreatic adenocarcinoma. Co-author DOI 10.1016/j.ejso.2020.07.029↗
  4. Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer: Subgroup Analyses of Patient, Tumor, and Previous Treatment Characteristics in the Pivotal NAPO… Co-author DOI 10.1097/mpa.0000000000001455↗
  5. Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korea… Co-author DOI 10.1177/1758835919871126↗
  6. Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospect… Co-author DOI 10.1097/sla.0000000000002705↗
  7. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, rand… Co-author DOI 10.1016/s0140-6736(15)00986-1↗
  8. Erlotinib plus gemcitabine versus gemcitabine for pancreatic cancer: real-world analysis of Korean national database. Last author DOI 10.1186/s12885-016-2482-z↗
  9. More Accurate Prediction of Metastatic Pancreatic Cancer Patients' Survival with Prognostic Model Using Both Host Immunity and Tumor Metabolic Activity. Co-author DOI 10.1371/journal.pone.0145692↗
  10. The Impact of Diabetes Mellitus and Metformin Treatment on Survival of Patients with Advanced Pancreatic Cancer Undergoing Chemotherapy. Co-author DOI 10.4143/crt.2014.292↗
  11. Concurrent Chemoradiotherapy Versus Chemotherapy Alone for Unresectable Locally Advanced Pancreatic Cancer: A Retrospective Cohort Study. Co-author DOI 10.4143/crt.2015.226↗
  12. Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index. Co-author DOI 10.1371/journal.pone.0139749↗
  13. Efficacy of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) in the treatment of patients with gemcitabine-pretreated pancreatic cancer and analy… Co-author DOI 10.1007/s00280-011-1584-1↗

Closest collaborators

The 25 strongest of 45 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Do‐Youn Oh · 10 shared papers, 2011–2023 · strength 0.82
  2. Seock‐Ah Im · 6 shared papers, 2011–2021 · strength 0.37
  3. Yung‐Jue Bang · 6 shared papers, 2011–2021 · strength 0.37
  4. Eui Kyu Chie · 4 shared papers, 2016–2021 · strength 0.34
  5. Younak Choi · 5 shared papers, 2015–2019 · strength 0.31
  6. Jin‐Young Jang · 3 shared papers, 2018–2021 · strength 0.29
  7. Jae Young Lee · 1 shared paper, 2023 · strength 0.19
  8. Dong Ho Lee · 1 shared paper, 2023 · strength 0.19
  9. Dong‐Hyuk Park · 1 shared paper, 2023 · strength 0.19
  10. Sang Hyub Lee · 1 shared paper, 2023 · strength 0.19
  11. Sun‐Whe Kim · 2 shared papers, 2018–2021 · strength 0.18
  12. Sung Whan Ha · 2 shared papers, 2016–2021 · strength 0.17
  13. Wooil Kwon · 2 shared papers, 2018–2020 · strength 0.17
  14. Kyubo Kim · 2 shared papers, 2016–2020 · strength 0.16
  15. Joon Oh Park · 2 shared papers, 2018–2019 · strength 0.14
  16. Kim Js · 1 shared paper, 2021 · strength 0.12
  17. Hongbeom Kim · 1 shared paper, 2020 · strength 0.11
  18. Haeryoung Kim · 1 shared paper, 2020 · strength 0.11
  19. Byoung Hyuck Kim · 1 shared paper, 2020 · strength 0.11
  20. Jean‐Frédéric Blanc · 1 shared paper, 2020 · strength 0.11
  21. Andrew Peter Dean · 1 shared paper, 2020 · strength 0.11
  22. Bruce Belanger · 1 shared paper, 2020 · strength 0.11
  23. Gyorgy Bodoky · 1 shared paper, 2020 · strength 0.11
  24. Li‐Tzong Chen · 1 shared paper, 2020 · strength 0.11
  25. Jens Thomas Siveke · 1 shared paper, 2020 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.